Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis

R Nicolai; E Cortis; L Ravà; C Bracaglia; M Pardeo; A Insalaco; P S Buonuomo; A E Tozzi; F De Benedetti

doi:10.1093/jpids/piu078

Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis

J Pediatric Infect Dis Soc. 2016 Mar;5(1):76-9. doi: 10.1093/jpids/piu078. Epub 2014 Jul 31.

Authors

R Nicolai¹, E Cortis², L Ravà³, C Bracaglia¹, M Pardeo¹, A Insalaco¹, P S Buonuomo⁴, A E Tozzi³, F De Benedetti¹

Affiliations

¹ Division of Rheumatology.
² Division of Pediatrics, Ospedale Santa Maria della Stella, Orvieto, Italy.
³ Division of Epidemiology, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.
⁴ Division of Rare Diseases, Department of Pediatric Medicine.

PMID: 26908493
DOI: 10.1093/jpids/piu078

Abstract

Incidence rates for varicella and herpes zoster were similar in patients with juvenile idiopathic arthritis receiving etanercept/methotrexate (n = 85, 184.9 patient-years [PY]) or methotrexate alone (n = 71, 199.4 PY); no complicated varicella or herpes zoster cases were reported; herpes labialis incidence was higher in patients receiving etanercept/methotrexate versus methotrexate alone (0.38 vs. 0.24 PY).

Keywords: etanercept; herpes simplex virus; juvenile idiopathic arthritis; varicella zoster virus.

Publication types

Observational Study

MeSH terms

Antirheumatic Agents / therapeutic use*
Arthritis, Juvenile / drug therapy*
Chickenpox / epidemiology*
Child
Child, Preschool
Drug Therapy, Combination
Etanercept / therapeutic use*
Female
Herpes Labialis / epidemiology*
Herpes Zoster / epidemiology*
Humans
Incidence
Male
Methotrexate / therapeutic use*
Rome / epidemiology
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antirheumatic Agents
Tumor Necrosis Factor-alpha
Etanercept
Methotrexate